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 ABSTRACT 
 
 
Evaluation of Self-Adjuvanting M2e Vaccine Efficacy in Response to Influenza A Virus 
Challenge  
 
Dustin Heiden  
 
Thesis Director: Victor Huber, Ph.D.  
 
 Influenza is a negative-sense, ssRNA virus composed of 8 segments, and it is 
responsible for numerous cases of morbidity and mortality around the globe.  As of today, 
vaccines are the best method to limit the pathogenesis of influenza viruses. Typically, 
influenza vaccines tend to incorporate hemagglutinin (HA) and neuraminidase (NA) 
surface proteins, and some can be complemented with a form of an adjuvant.  However, 
HA and NA are problematic vaccine candidates due to their high susceptibility to mutate 
using antigenic drift and to change their genetic makeup using antigenic shift. The frequent 
alterations in HA and NA require a substantial amount of resources being utilized in the 
surveillance and subsequent bi-annual adjustment of the influenza vaccine administered to 
the public. To improve vaccine consistency, researchers are exploring the concept of a 
universal vaccine based on conserved components of the influenza virus, such as the 
hemagglutinin stalk and the ectodomain of the M2 (M2e) ion channel. Thus far, it has 
been shown that 9 out of 24 amino acids that constitute M2e are highly preserved and 
rarely exhibit mutations, making it a prominent candidate for vaccines.  Investigating the 
immunogenic effects of a self-adjuvanting, liposome-based M2e vaccine in ferrets will shed 
light on whether M2e would be an effective vaccine candidate. 
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CHAPTER ONE 
 
Introduction: 
 
The History and Importance of the Influenza Virus: 
 The Influenza A virus (IAV) is a respiratory pathogen that is easily transmitted from 
diseased patients to other vulnerable hosts via contact with and uptake of respiratory 
droplets (Deng, et al. 2015).  The virus manipulates its host into producing more of its 
progeny, which in turn can lead to severe states of morbidity or even mortality (Dou, et al. 
2018).  The greatest of influenza pandemic dates back to the years 1918-1920, when a 
deadly outbreak of an H1N1 virus, more commonly known as the “Spanish Flu”, resulted 
in the estimated deaths of 40-50 million people worldwide (Johnson and Mueller 2002).  
Since the 1918 pandemic, the human population has endured many other pandemics that 
were characterized by the emergence of new viral subtypes, including H2N2 in 1957, 
H3N2 in 1968, and new strains of H1N1 in 1977 and 2009 (Zimmer and Burke 2009). 
These strains are more commonly known as the Asian Flu (1957), Hong Kong Flu (1968), 
Russian Flu (1977), and the Swine Flu (2009) (McCormick 2015).  According to the World 
Health Organization, there are approximately 5 million severe cases of influenza 
contributing to the death of about 650,000 individuals yearly (“Influenza (Seasonal), 2019).  
Many of the mortalities are not restricted to only primary viral infections but are the result 
of secondary bacterial superinfections (Huber, et al.  2011).  
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Influenza Replication Cycle: 
 The IAV is an enveloped, negative-sense, single-stranded RNA (ssRNA) virus that 
belongs to the Orthomyxoviradae family of viruses (Samji 2009).  This pathogen comes in 
four types that are differentiated based on three main factors: their structure, proteins 
expressed, and the hosts that it affects (McCormick 2015).  These four types are termed 
influenza A, influenza B, influenza C, and influenza D (Zimmer and Burke 2009).  
Currently, the most prominent virus type of concern is the IAV because it is the only viral 
type that is known to infect between species and generate pandemics in humans (Dou 
2018).  IAV is composed of eight segments: RNA Basic Polymerase 1 (PB1), RNA Basic 
Polymerase 2 (PB2), matrix proteins (M), nucleoprotein (NP), neuraminidase (NA), RNA 
Acidic Polymerase (PA), non-structural proteins (NS), and hemagglutinin (HA) as shown 
below in Figure 1(Klonoski 2018).  Using these 8 genetic segments, the influenza virus 
produces approximately twelve proteins (Bouvier and Palese 2008). Upon infecting hosts, 
the influenza virus employs an acute infection cycle in which the pathogen will enter a host 
cell and manipulate its cellular machinery into producing replicates of itself (Zheng, Zhang, 
Guo, and Tao 2016).  This process is characterized by a series of major events as follows: 
entry into the host cell; entry of viral ribonucleoproteins into the nucleus; transcription and 
replication of the pathogen; nuclear export; and assembly and budding at the cellular 
plasma membrane (Matsuoka 2013). 
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Figure 1: An Image showing the eight segments present in IAV and the major surface proteins, HA, NA, and 
M2 ion channel proteins (Wilson 2018). 
 
 For an IAV to commandeer cells, it utilizes one part of HA surface glycoprotein, 
known as the globular head region (HA1), to bind to the sialic acid residues (N-
acetylneuraminic acid) coating the plasma membrane of the host cell (Vigerust 2011).  
Once bound to the surface of the cell, the influenza virus is taken up via receptor-mediated 
endocytosis (Matsuoka, et al. 2013).  During the process of endocytosis, the pathogen is 
packaged into an endosome.  Due to the endosome being a more acidic environment (pH 
between 5 and 6), the influenza virus undergoes a conformational change in the HA 
protein causing the exposure of the second subunit known as the stalk region or HA2 
(Samji 2009).  The HA stalk domain fundamentally functions to combine the viral 
envelope with the interior of the endosome.  Following the fusion of the endosome with 
virus’s envelope, the M2 ion channels are opened allowing protons to enter the virion, thus 
leading to the acidification of the of the pathogen’s core (Pinto and Lamb 2005).  In 
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response to the pH change, the viral ribonucleoproteins (vRNP) are ejected into the 
cytoplasm of the cell (Zheng, et al. 2016).  
 Upon entry into the cytoplasm, the viral contents follow a series of nuclear 
localization signals that lead it to the host cell’s nucleus (Boulo, et al. 2007).  Once in the 
nucleus, many key events must occur for successful viral replication.  First, the negative-
sense ssRNA IAV is coded in a positive direction by the pre-packaged RNA-dependent 
RNA polymerase enzyme, so the influenza virus can utilize the host’s cellular machinery 
(Li, et al. 2001).  During the positive coding process, the virus, through a method termed 
“cap-snatching,” in an act of thievery will take the 5’ methylated cap of pre-mRNA and use 
it to prime viral RNA for transcription (Dou, et al. 2018).  Concurrently, other NS proteins 
actively work to prevent the exportation of host mRNA while viral RNA are free to exit the 
nucleus (Matsuoka, et al. 2013).  With the cell has been successfully commandeered, the 
focus shifts to the translation of viral proteins from viral mRNA (Bui, et al. 2000).  After 
the synthesis of viral proteins, IAV-associated proteins are transported to the endoplasmic 
reticulum and the golgi apparatus for final post-translational modifications (Vigerust 2011).  
Then, IAV constituents converge on the plasma membrane.  The HA, NA, and M2 
proteins integrate themselves into the host plasma membrane through associations with 
lipid rafts, therefore marking the site of budding (Boulo, et al. 2007).  The M2 proteins, 
using its cytoplasmic tail, works in tandem with M1 proteins, contributing through lipid 
interactions, to package the vRNP into the completed virion (Iwatsuki-Horimoto, et al. 
2006).  Finally, through M2 mediated membrane interactions, the virion exits the host cell 
by budding (Samji 2009).  During this process, NA proteins cleave sialic acid residues, so 
the IAV avoids immediate agglutination and can successfully leave the host cell (Nayak, et 
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al. 2009).  It is important to note that during the infection cycle, all three proteins 
expressed on the surface of the virus, HA, NA, and the 23 amino acids of M2 (M2e) are 
expressed on the surface of infected cells. The viral replication process is shown in Figure 2 
below.  
 
 
Figure 2: Qiagen© diagram depicting the influenza infection cycle (Qiagen, Influenza A Virus Replication 
Cycle 2009). © 2009 QIAGEN, all rights reserved 
 
 
11 
 
 
An Overview of the History of Influenza Vaccines:  
 Influenza Pandemics occur because of the emergence of a novel influenza virus and 
a lack of immunity among the host population (Lambert and Fauci 2010).  In the early 
1930’s, scientists were able to successfully isolate the influenza virus from humans 
(McCormick 2015).  This event was the first major step in the development of the 
influenza vaccine movement, and by the 1940’s, the first inactive bivalent vaccine 
containing the of influenza A and B was developed, and these were grown in embryonated 
chicken eggs (Hannoun 2013).  Around the same time, live-attenuated vaccines first 
entered clinical trials (I. Barberis, et al. 2016).  The viruses used for live-attenuated vaccines 
were primarily grown in chicken eggs as is standard today as well, and by the end of the 
decade, a protocol for growing influenza viruses using in-vitro methods had been 
developed (Hannoun 2013).  In 1952, the influenza first surveillance program was 
established with the purpose of watching for antigenic drift in the virus, particularly HA, 
and the emergence of new viral strains (“Influenza (seasonal)” 2019).  Due to the 
reactogenicity of whole virus vaccines, there was a push for bettering the technique using 
the reassortment of influenza viruses onto a less-virulent laboratory strain (Parkman, et al. 
1977) and creation of split and subunit vaccines.   
 In the next decade, the development of two new types of vaccines, the split vaccine 
and the subunit vaccine, were initiated (Krammer and Palese 2015).  Initially, split vaccines 
were utilized leading into the seventies, but it was found that this style of vaccination was 
less immunogenic than its whole virus complement when it came to individuals who had 
never been inoculated.  As a result, individuals receiving the vaccine for the first time had 
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to receive additional vaccine boosters (Parkman, Hopps, Rastogi, and Meyer 1977).  By the 
late seventies the first inactive, trivalent subunit vaccines were developed.  These vaccines 
contained only the HA and NA surface antigens of the H1N1, H3N2, and influenza B 
viruses and were advantageous over their split vaccine predecessor due to an increased 
level of immunogenicity (Kendal, Maassab, Alexandrova, and Ghendon 1987).  However, 
two administrations of the vaccine were still required on first vaccination to ensure 
protection during epidemics (Gianchecchi, Trombetta, Piccirella, and Montomoli 2016).   
 In the last twenty years, vaccine technology has rapidly improved. FluMist®, a live-
attenuated vaccine, was introduced as a means of intranasal inoculation in the early 2000’s 
(Barberis, et al. 2016). By 2009, the FDA approved the usage of the MF-59 adjuvant-
enhanced vaccines for young children because they are still building immunity and geriatric 
individuals due immunosenescence (Soema, Kompier, and Amorij 2015).  An additional 
two years of vaccine research resulted in the approval of intradermal vaccine delivery. This 
new method of vaccinating proved to be better than previous intramuscular injections 
because it elicited a stronger innate and adaptive immune response through the 
enhancement of antigen presenting cell activity (Duarando, et al. 2011).  In the next year, 
the first quadrivalent vaccine, Fluarix®, was approved for public use.  Fluarix® had two 
influenza A strains and two influenza B antigens, providing the benefit of a reduction in 
viral mismatch and vaccine production while maintaining the standard set by trivalent 
vaccines (Belshe 2010).  By 2013, FluBlock®, a recombinant influenza vaccine, was 
approved by the FDA for use in people between the ages of 18 and 49 years of age (Baxter, 
et al. 2011). Each of these vaccines work through the induction of immunological memory 
against HA in the form of memory T cells and antibodies (Pica and Palese 2013).  
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According to the Center for Disease Control (CDC), influenza vaccine administration in 
2017-2018 prevented 7.1 million cases of morbidity and at least 8000 deaths, making 
vaccines the best method of controlling influenza outbreaks and offsetting the potential 
devastating effects of the virus (“Influenza (flu)”, 2019).   
  
Universal Vaccine Initiative: 
 Influenza has the tendency to change through antigenic drift and antigenic shift, 
causing epidemics and pandemics, respectively (McCormick 2015). When these new 
viruses emerge, humoral and cell mediated immune responses may not recognize them, 
and new vaccines have to be developed both annually and in the face of a pandemic 
(Staneková and Varečková	2010).  However, certain proteins, such as the ectodomain of 
the M2 (M2e), are well preserved from an evolutionary standpoint (Pica and Palese 2013).  
It is the conserved protein epitopes of influenza viruses that have caught the attention of 
immunologists today, as they could be potential constituents for the development of 
universal influenza vaccines (Schotsaert, et al. 2009).  The overarching goal of the universal 
vaccine initiative is the production of an influenza vaccine that generates lifelong protection 
against all strains of the influenza pathogen, with influenza A virus being the most 
important target due to its contribution to pandemics (Fiers, et al. 2009). By vaccinating 
using conserved proteins, like M2e, broad immunity in the form of M2e specific 
antibodies, specifically IgA and IgG, and cell mediated responses, can be induced against 
most influenza strains using a single vaccine (Lambert and Fauci 2010).  However, M2e by 
itself does not elicit a strong immune response during natural infection (Pica and Palese 
2013), and antibodies against M2e do not neutralize the virus.  In order to increase the 
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immunogenicity of M2e vaccines, and allow antibodies induced to kill infected cells 
through antibody-dependent cellular cytotoxicity, or ADCC (Van den Hoecke 2017), an 
adjuvant needs to be incorporated into the vaccine (Filette, et al. 2006).  It is hypothesized 
that by inoculating ferrets (Mustela putorius furo) using a liposome-based vaccine 
containing diptheria toxoid (DT), IAV peptide antigen derived from M2e, and the 
immunostimulatory synthetic glycolipid, Monophosphoryl 3-Deacyl Lipid A (3D-PHAD®), 
that immunity will be induced against the influenza A virus, A/California/04/2009 (Ca09), 
illustrating the potential for a self-adjuvanting, universal liposomal flu vaccines.   
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CHAPTER TWO 
 
Methods and Materials: 
 
M2e-Lipo-DT+PHAD Vaccine Design: 
 
    
Figure 3: A theoretical image depicting the structure of the M2e-Lipo-DT+PHAD vaccine, with M2e being 
the component of influenza A expressed on the liposome.   
 
 The liposomal influenza vaccine platform (M2e-Lipo-DT+PHAD) utilized in this 
study was designed and provided by collaborators, Mehfuz Zaman, et al., at Griffith 
University, Australia (Zaman, et al. 2016).  This vaccine is a spherically-shaped liposome 
made of neutrally charged, biocompatible phospholipid bilayers that were prepared as 
described (Zaman, et al. 2016).  Various charged peptides are embedded in the liposome’s 
surface.   Protein spacers, termed SSK, act as antigen carriers and are covalently bonded to 
two palmitic acid molecules that have been integrated into the liposomal membrane.  The 
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IAV M2e peptide was attached to the SSK spacers via the N-terminus.  Each inoculant of 
liposomes contained approximately 16 µg of antigenic peptides per mL.  3D-PHAD® has 
been inserted into the membrane of the liposome using the lipid moiety extant in the 
glycolipid.  The total concentration of glycolipid per mL was 13 µg. Inside the particle, 
resides the adjuvant diptheria toxoid (DT).  DT serves two functions. The first is that 
lipidated peptides, such as DT, are targets for B cell antigen presentation, which in turn 
activates CD4+ cells.  The second purpose of DT is the formation of modular epitopic 
constructs that activate IgA producing B cells.  Each vaccine particle housed approximately 
16 µg of DT content per mL.  Overall phospholipid content was calculated to be around 1 
mg/mL (Zaman, et al. 2016). This was assessed by collaborator, Mehfuz Zaman (Griffith 
University, Australia).  A visualization of the vaccine construct is illustrated above in Figure 
3.  
Ferrets:  
 Six young adult, male ferrets from an influenza-free ferret colony at Marshall Farms 
were brought into the University of South Dakota (USD) Sanford School of Medicine’s 
animal facilities.  The ferrets were allowed to acclimate for fourteen days. Following the 
acclimation period, all ferrets were tested to confirm that antibody levels were below a titer 
of 10 against A/California/04/2009 (Ca09), indicating that they were seronegative against 
the challenge virus at the time of vaccination.  All procedures and experiments carried out 
were done so within biosafety level 2 facilities and in accordance to parameters set 
individually by the Institutional Animal Care and Use Committee and the Institutional 
Biosafety Committee of USD.  
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Vaccine Preparation and Administration:  
 The M2e-Lipo-DT+PHAD M2e vaccine was received from collaborators in a 
freeze-dried condition as previously described (Zaman, et al. 2016).  Initially, the vaccine 
contents and Dulbecco’s Phosphate Buffered Saline (DPBS) were heated at 37°C for 5 
minutes prior to adding 3.2 mL of DBPS to the dehydrated vaccine.  Once added, the 
solution was mixed until a homogenous, cloudy mixture absent of bubbles was formed. 
This was repeated 3 times for the M2e vaccine and an additional 3 times for the blank 
liposome vials.  Next, the ferrets were anesthetized using an isoflurane (4.5%) vaporizer as 
previously described (Huber, Kleimeyer, and McCullers 2008).  Three of the ferrets were 
inoculated intranasally with 0.5mL per nostril of M2e-Lipo-DT+PHAD vaccine and held 
upright for 10-15 seconds to ensure the vaccine made it to the lungs. The inoculation 
process was repeated for the other three ferrets, using blank liposome solution.  Ferrets 
were observed for 34 days post-vaccination and received booster inoculations on days 14 
and 21 that were delivered as described for initial vaccine delivery.  During this 34-day time 
period, sera were collected from ferrets on days 7, 14, 21, 28, and 34 and tested using HAI 
in a manner previously described (Huber and McCullers 2006), and Enzyme-linked 
Immunosorbent Assays (ELISA) as described below.   
Serum Treatment: 
 Prior to, during, and after vaccination and subsequent viral challenge, the serostatus 
of the six ferrets were tested.  Each ferret was subjected to isoflurane (4.5%) vaporization 
(Thermo Fisher Scientific) anesthesia individually.  While anesthetized, approximately 
1mL of serum was collected from the mammary vein of each ferret and allowed to clot for 
3 hours at room temperature.  Following serum collection, ferrets were observed for 10 
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minutes to ensure their recovery.  The clotted blood samples were then centrifuged using 
an accuSpin Micro 17R tabletop centrifuge (Fisher Scientific) for 10 minutes at 6,000 
RPMs to further separate the sera from the clotted cells.  Then, 100uL of sera from each 
ferret was pipetted into separate 1.5 mL microcentrifuge tubes (Fisher Brand) and 300 µL 
of Receptor Destroying Enzyme (RDE) solution (Denka Seiken Co.) was added to each 
tube, as previously described (Cwach, Sandbulte, Klonoski, and Huber 2011).  The RDE-
treated samples were incubated overnight at 37°C.  The next day, 300 µL of a 2.5% 
sodium citrate solution was added to each RDE-treated sample and incubated at 56°C to 
further reduce the interference of innate inhibitors naturally present in ferret serum.  After 
incubation, 300 uL of 1x Phosphate Buffer Solution (PBS; pH = 7.43) was added to the 
ferret sera solutions prior to adding 50 uL of packed chicken red blood cells (CRBCs) to 
pre clear the sera of inhibitors that interact with CRBCs.  The samples were placed at 4°C 
for one hour, with intermittent mixing occurring every 15 minutes.  Sera were removed 
from CRBCs through centrifugation at 1,000 RPM for 10 minutes, and the treated ferret 
sera were then used for HAI assays, microneutralization assays, and ELISAs as described 
below. 
HAI Assay: 
 The HAI assay was utilized to test the reactivity of the serum collected from ferrets.  
This technique was performed using a Ca09 virus stock that had been diluted to a 1:8 ratio 
based on HA content pre-determined by a Hemagglutinin assay, as previously described 
(Cwach, Sandbulte, Klonoski, and Huber 2011).  After achieving the desired HA content, 
treated sera from vaccinated and unvaccinated ferrets were added to wells in column 1, A 
through F, of a non-sterile 96-well round bottom plate. 25 µL of 1x PBS (pH=7.43) were 
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added to each respective well in columns 2 through 12.  The sera present in column 1 was 
serially diluted out across the wells 2- through 12.  Next, 25 µL of diluted Ca09 virus was 
added to each well and was left to incubate at 4°C for 1 hour.  The final volume in each 
well after the addition of the virus was 50 µL.  Following the incubation period, 50 µL of 
0.5% CRBC solution was added to each well and the plates were left to incubate at room 
temperature for 30 minutes.  If a pellet is observed, then the hemagglutinin lattice 
formation by viral interactions with sialic acid residues present on CRBC has been 
inhibited by the presence of antibodies against Ca09 HA, denoting seroreactivity. If a pellet 
does not form and agglutination occurs, the virus was able to bind to CRBC illustrating that 
antibodies against Ca09 were not present at that dilution of sera.   
 
Microneutralization Assay: 
 The microneutralization assay was performed as previously described (Cwach, 
Sandbulte, Klonoski, and Huber 2011).  As the first step, a 96 well, flat bottom plate 
(Falcon) was seeded with 100 µL of Madin-Darby Canine Kidney (MDCK) cells in growth 
media at a concentration of 3.00 X 105 per mL and allowed to incubate overnight at 37° C 
with 5% CO2.  The next day, 60 µL of MDCK infection media was added to the whole 
plate except for column 1.  Row H and column 12 were reserved for a cell control and 
Ca09 virus back titration respectively.  To complete the cell controls, an additional 60 µL 
of MDCK infection media was added to row H.  120 µL of RDE-treated sera from each 
ferret was added to A1 through G1.  Using the sera added to column 1, a serial, 1:2 
dilution scheme was established across the plate with the exception of the column 12.  
Next, the viral back titration was prepared by adding 438 µL of Ca09 influenza virus, with a 
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previously determined TCID50 value of 100, to a sterile Eppendorf tube.  Then 138 µL 
from the previously mentioned tubes was serially diluted out through 6 other tubes.  The 
total volume of each Eppendorf tube following the serial dilution of the Ca09 virus should 
be 300 µL. 60 µL of diluted virus from each tube was added, in order, to column 12 with 
the highest concentration in A12 and the lowest in G12.  The total volume present in each 
well following the addition of the previous solutions was 120 µL.  The 96 well plate was 
incubated at 37° C in a 5% CO2 atmosphere for 2 hours to allow the virus and sera to 
interact.  
 Prior to inoculation with the virus:serum dilutions, created as described above, the 
supernatant was aspirated off of the 96 well plate containing MDCK cells that was prepared 
the previous day.  The MDCK monolayers were washed with 200 µL of 1x, sterile PBS 
(pH = 7.43) two times.  Next, supernatant containing Ca09 and RDE treated sera was 
transferred from its original plate to the 96 well plate containing MDCK cells.  The cells 
antibody:virus mixtures were incubated at 37° C in a 5% CO2 environment for two hours.  
Afterward, the plate with cells was rinsed with 200 µL of MDCK infection media.  Finally, 
100 µL of MDCK infection media supplemented with TPCK trypsin at a concentration of 
2 µg /mL was added to the cells, and they were incubated overnight in a 37° C, 5% CO2 
environment.  
 The next day, the media was removed from the cells and replaced with 125 µL of 
sterile, 1x PBS twice as a method of washing the cells.  Cells were then fixed to the plates 
using 100 µL of ice-cold fixative solution (80% acetone in 1x PBS) and left at room 
temperature for 10 minutes. After incubation, the fixative solution was removed, and the 
plate was allowed to air dry for 20 minutes.  Plates were subject to a series of three washes 
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using wash solution (1x PBS + 0.05% Tween-20). Post-cleanse, cells were incubated in an 
antibody diluent buffer containing primary, mouse anti-NP monoclonal antibody 
(Millipore) in a 1:2000 ratio with 1x PBS, Bovine Serum Albumin (BSA), and tween-20 for 
1 hour at room temperature.  Following incubation, cells were washed with wash buffer 
four times.  100 µL of a secondary, polyclonal goat anti-mouse IgG-HRP antibody solution 
(1:2000, antibody: diluent solution; Sigma Aldrich) was added to the plate, which was 
incubated at room temperature for 1 hour. The plate was washed in a manner previously 
described six times. 100 µL of substrate buffer containing o-Phenylenediamine 
dihydrochloride (OPD) substrate, and hydrogen peroxide was utilized to activate the HRP 
attached to the secondary antibody.  After 5 minutes of development, a color change from 
clear to yellow was denoted in samples that were positive, and 100 µL of a stop solution 
containing 1 N sulfuric acid was added to the plates. Plates were read using a Bio Tek 
Synergy HT plate reader at an absorbance of 490 nm. Absorbances collected were used to 
calculate the total amount of viral neutralization occurring.   
 
M2e ELISA: 
 The ELISA was another method utilized for the detection of IgG/IgA antibody 
levels present in ferret sera pre-vaccination through post-vaccination and pre-challenge 
through post-challenge with Ca09, using methods similar to those previously described 
(Huber, Thomas, and McCullers 2009).  Due to the nature of the ELISA, each test 
occurred over the course of three days.  On day one, M2e peptide antigen in the form of 
the vaccine described above (Figure 3) was thawed on ice and diluted to a concentration of 
10 µg /uL in 1x sterile PBS (pH=7.43).  This process was repeated for the blank 
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liposomes.  50 µL of the InA antigen solution and blank liposome solution were added to 
their own 96 well flat bottom Maxisorp® ELISA plates.  The plates were covered using 
para-film and stored at 4°C and incubated overnight to allow for the coating of the plates 
with their respective antigens.  
 On day 2 of the ELISAs, plates were removed from the 4°C and warmed to 
ambient temperature. The current solutions in the wells of the plates were removed and 
the plates were washed six times using a 200 µL of a 0.05% wash buffer (1x PBS in Tween-
20, PBS-T). Following the washes, 100 µL of blocking buffer (10% FBS + PBS-T) was 
added to each of the wells to increase the sensitivity of the assay.  The plates were para-
filmed to prevent them from drying out and incubated at room temperature for 2 hours.  
Blocking buffer was removed and 50 µL of blocking buffer was added to all wells except 
those in the first column.  80 µL of blocking buffer along with 20 µL of the respective 
ferret sera sample was added to the first well. This 1:5 dilution of ferret sera that had been 
already diluted 1:10 through the RDE-treatment steps described above, made the initial 
serum dilution used in the ELISA a 1:50.  The solution present in column 1 was serially 
diluted across columns 2 through 12 by transferring 50 µL of solution from the previous 
well to the next well, with the exception of H12 which was reserved as a blank.  The plates 
were para-filmed once more and stored overnight at 4°C.  
 Day 3 of ELISA started with six washes using PBS-T as previously described.  Next, 
primary, monoclonal antibody containing goat anti-ferret IgG (Thermo Scientific) was 
diluted in the 10% FBS in PBS-T blocking buffer at a 1:1,000 dilution.  50 µL of primary 
antibody solution was then applied to the plates prior to incubation for 1-hour incubation 
at room temperature.  Plates were then washed with PBS-T to clear excess antibodies out 
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of the wells.  Next, 50 µL of secondary, polyclonal rabbit anti-goat IgG-AP antibody 
(Cappel) solution was added to the wells at a 1:1,000 dilution and the plates were incubated 
for 1 hour at ambient temperature. Plates were washed in a manner previously described, 
and substrate buffer (1M Diethanolamine, pH = 9.8) was mixed with p-nitrophenyl 
phosphate tablets (1 tablet per 5 mL of substrate buffer, 1 mg/mL). The tablets were 
allowed to dissolve in a dark area to prevent premature photo reactivity. Once prepared, 50 
µL of the substrate solution was added to each well. The plates were left at room 
temperature in the light to allow for development. Finally, the plates were read using at 405 
nm using the EL808 plate reader (Bio-Tek). This process was repeated for ferret sera 
collected at days 0, 7, 14, 21, and 34 to characterize IgG and IgA response to the M2e-
Lipo-DT+PHAD influenza A vaccine.  This same process was also utilized to measure the 
IgA and IgG humoral response using sera collected days 1, 3, 5, and 7 post Ca09 
challenge.   
Ferret A/California/04/2009 Challenge and Observations: 
 
 Following the vaccination time period, the ferrets were challenged with the Ca09 
virus at a dosage of 106.25 infectious particles/mL.  The virus was diluted to the inoculation 
dose 2using in 1x sterile PBS (pH=7.43), and 1 mL was administered intranasally to each 
anesthetized ferret (0.5 mL per nostril).  After the intranasal inoculation with Ca09, ferrets 
were held upright for 10-15 seconds to ensure proper delivery of the pathogen.  Over the 
8-day course of the study, ferret symptoms related to influenza morbidity, specifically 
activity levels and sneezes, were observed as previously described (Huber and McCullers 
2006).  In relation to activity level, a score of 0 was given to ferrets that were alert and active 
without stimuli, a 1 was ascribed to ferrets who were alert, but required stimulus to be 
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playful, a 2 was given to ferrets that were alert, but not active despite the application of 
stimuli, and a 3 was given to ferrets were neither alert or playful.  As for sneezes, a score of 
0 was denoted for ferrets who did not sneeze.  Ferrets who sneezed 1 to 10 times were 
given a score of 1. A score of 2 was assigned to ferrets that sneezed more than 10 time. A 
score of 3 was given to ferrets who display signs of respiratory distress.  These scores were 
ascertained over a 10-minute observation period and served as a clinical score for ferrets, 
and the maximum value for this clinical score was 6.  The daily temperature and body 
weight of each ferret was measured daily as additional ways to gauge the severity of 
infection.  
Assessment of Viral Load Present in Ferrets: 
 To assess the viral load present in a ferret, their nasal washes were collected daily 
following the Ca09 challenge, as previously described (Huber and McCullers 2006).  Prior 
to collecting nasal washes, ferrets were anesthetized using isoflurane (4.5%) vaporization 
and subsequent application of ketamine (Hospira) at a concentration of 30 mg/kg.  Besides 
anesthesia, the administration of ketamine serves an accessory function of keeping the 
sneeze reaction intact.  After anesthetizing the ferrets, 0.5 mL of PBS per nostrils was 
intranasally instilled.  The response in the form of a sneeze was collected in 50-mL Tubes 
(Corning).  To test the viral load present in the nasal fluid, MDCK cells grown at a 
concentration of 3.0x105 per mL were plated on 48-well plates (Falcon).  These plates 
containing confluent monolayers of MDCK cells were washed two times with 500uL of 1x 
sterile PBS. Infected with the nasal washes.  Next, 50 µL of serially diluted (1:10) nasal 
wash was pipetted onto the cellular monolayers and left to rock gently on a Rocker 35® 
(Labnet) for 1 hour with intermittent plate taps every 15 minutes.  Following the rocking 
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period, the inoculum was removed and supplanted by MDCK infection media 
supplemented with 1 µg/mL L-(tosylamido-2-phenyl) ethyl chloromethyl ketone-treated 
trypsin (TPCK-Trypsin; Worthington Biomedical). The cells were incubated at 37°C in 5% 
CO2. Viral titers were reported as TCID50 per milliliter of nasal wash fluid. While 
cytopathic effects (CPE), characterized by cellular morphology and destruction of the 
monolayer, can be utilized to qualitatively signify the presence of a virus in vitro, to 
accurately quantify the virus concentration present in the ferret nasal wash samples, a 
confirmation of the virus present in supernatant is done.  This step involves taking 50 µL of 
supernatant from the 48-well plate (Falcon) that has been inoculated and incubate for 72 
hours and transferring it to a 96-well round bottom plate (Fisherbrand).  Next, 50 µL of 
0.5% chicken red blood cell (CRBC) solution was added to the wells containing 
supernatant.  The plate was then incubated at room temperature for 30 minutes.  After the 
incubation period, the presence or absence of the influenza virus is identified.  The results 
of a HA assay are read in opposition to the manner in which HAI assays are read.  A 
negative result is characterized by a pellet forming at the bottom of the well.  A positive 
result is marked by the lattice formation known as hemagglutination of CRBC due to HA 
interactions with the sialic acid residues present on the CRBC.  The number of positive 
wells can then be used to calculate a TCID50 value of the virus.   
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CHAPTER THREE 
Results: 
 
                 
Figure 4: M2e-based ELISAs illustrate the differences between vaccinated and unvaccinated (blank liposome) 
ferrets regarding anti-M2e antibody levels produced.  
 
                
Figure 5: Results from M2e-based ELISAs exhibit the differences in IgG antibody production in ferrets who 
were vaccinated using the M2e-Lipo-DT+PHAD vaccine and ferrets who received blank liposome 
(unvaccinated).  
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Figure 6: Microneutralization assay assessment shows that neither ferret sera contained antibodies capable of 
neutralizing Ca09 viruses in vitro prior to the viral challenge. Note that the unvaccinated group and vaccinated 
group had the same titers. As a result, one group is covering the other. 
 
                        
 
Figure 7: HAI assay data illustrates that none of the ferrets produced antibodies capable of interacting with 
the HA surface protein of IAV. 
 
 
 
28 
 
 
 
Days Post Vaccination (DPV) Results:  
 
 One of the goals of the testing the efficacy of the M2e-Lipo-DT+PHAD vaccine 
was to assess its ability to generate an IgA and IgG humoral immune response against M2e.  
To achieve this aim, a group of ferrets were inoculated intranasally with the liposome-based 
vaccine.  Sera were collected on day 0 prior to vaccination and treated with RDE and 
sodium citrate solution to improve the sensitivity of the M2e-based ELISA.  Days 7, 14, 21, 
and 34 days post vaccination, sera were collected from the ferrets and treated in a manner 
previously described.  Following the collection of sera on days 14 and 21, the vaccine group 
of ferrets received an additional dosage of M2e-Lipo-DT+PHAD vaccine and the 
unvaccinated group was given a supplementary volume of blank liposome solution.  The 
RDE and sodium citrate treated-ferret sera were subjected to analysis via M2e-based 
ELISAs and microneutralization assays.  
 The M2e-based ELISA was utilized to assess the titers of anti-M2e IgA and anti-
M2e IgG levels present in the ferrets’ sera.  A 1:2 dilution scheme of treated sera was 
applied to 96 well, flat bottom plates and the absorbances, created from of each plate (one 
for each day) was ascertained.  Absorbance results obtained from EL808 plate reader were 
used to calculate the anti-M2e IgG and M2e IgA concentrations from each day before and 
after vaccine or blank liposome administration.  The results yielded from these assays on 
day 0 reveal that, initially, the ferrets had not seroconverted and thus were not producing 
IgA or IgG antibodies against the introduced InA M2e antigen.  This is shown on Figures 4 
and Figure 5, respectively.  These figures continue to illustrate the differences between 
vaccinated ferrets and blank liposome recipients. Days 7 and 14 of Figure 4 show a 
consistent level of IgA following vaccination.  After delivering the vaccine boosters on day 
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14 and 21, the IgA titers had a minimum 4-fold increase in comparison to the unvaccinated 
group (25 to 95).  By day 34, anti-M2e IgA titers spiked. The ferrets inoculated with blank 
liposomes, in comparison, did not express high levels anti-M2e IgA.  The M2e-based 
ELISA assessment, shown in Figure 5, showed that anti-M2e IgG was not present in the 
sera of any of the ferrets.  However, day 21, following the application of a vaccine booster, 
exhibited a minimum significant 10-fold increase in the concentration of anti-M2e IgG 
antibody in the vaccinated group, with IgG titers reaching as high as 771, compared to 
those inoculated with blank liposomes only.  By day 34, the anti-M2e IgG concentrations 
of the vaccinated group had tapered off, but still remained higher than the blank liposome 
group.  Overall, the group of ferrets that were vaccinated and received subsequent boosters 
showed an increase in their antibody response against the M2e antigen when compared to 
the complementary group who were given blank liposomes.  When blank liposomes were 
used as the coating antigen, antibodies were not detected for either the vaccinated or 
unvaccinated group, indicating that the blank liposomes alone were not immunogenic. The 
lack of immunogenicity against the blank liposomes was expected, because it is in line with 
previous findings (Zaman, et al. 2016) 
 To supplement the M2e-based ELISA results, the microneutralization assay was 
employed to assess the ability of the antibodies present in the treated-ferret serum to 
neutralize the virus that would be used in the next portion of the project to challenge the 
ferrets.  From the absorbances collected via the Bio Tek Synergy HT plate reader, the 
amount of Ca09 neutralized was calculated.  This assay revealed that despite the increase in 
production of anti-M2e IgG and IgA present in the ferret group that received the M2e-
Lipo-DT+PHAD vaccine, the virus was still able to replicate successfully.  The inability to 
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neutralize the Ca09 virus was illustrated in the unvaccinated group as well.  The 
relationship between neutralization and the days post vaccination is shown in Figure 6.   
 HAI assays were utilized post-vaccination to investigate whether ferrets were 
producing antibodies in serum that were capable of binding to HA surface proteins on the 
Ca09 virus.  After introducing CRBCs to plates containing virus and ferret sera from days 
0, 7, 14, 21, and 34 post-vaccination, agglutination was observed, which illustrates that the 
virus was still able to interact with the sialic acids present on CRBCs. These interactions 
indicate, that despite producing higher levels of anti-M2e IgA and IgG, that neither the 
vaccinated or unvaccinated ferret groups were mounting an anti-HA humoral immune 
response. The inability of the antibodies produced by either ferret group to interact with 
Ca09 HA is shown above in Figure 7. 
 
                      
 
Figure 8: Clinical scores are the summation of daily sneeze scores and activity scores post-challenge with the 
influenza virus, Ca09. Activity is scored on a scale of 0-3, with 0 being the most active and 3 being 
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unresponsive. Sneezes are scored on a scale of 0-3, with 0 being no sneezes and a score of 3 is characterized 
by acute respiratory distress.  
 
Days Post Infection (DPI) Results: 
 Following the 34-day post vaccination period, all ferrets were challenged with the 
influenza virus, Ca09 and observed for eight days.  During the 8-day post infection period, 
all ferrets were observed for 10 minutes.  During this observational period, the number of 
sneezes and activity level of each ferret was scored and summated into a daily clinical value 
shown in Figure 8.  The number of sneezes is used as a method to qualitatively assess that 
the ferrets are infected with the Ca09 virus and that they are successfully shedding the virus.  
The activity level of the ferrets is used a qualitative, auxiliary method used to gauge how the 
ferret is handling the infection.  A ferret who is infected with influenza tends to display 
more lethargic behaviors in direct correlation with the severity of the infection.  Based on 
the Figure 8, initially, the vaccinated ferrets were not as symptomatic as the unvaccinated 
ferrets, suggesting a resistance to infection.  By days 4 and 5 post infection, both ferret 
groups displayed consistent symptoms with one another. In terms of symptoms, by day 7 
post-infection, ferrets from the unvaccinated group appeared to have resolved the infection 
sooner than their vaccinated counterparts. Overall, all ferrets manifested symptoms of an 
influenza A virus challenge.  
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Figure 9: This model shows fluctuations in ferret temperatures, one of the common signs exhibited by the 
presence of an influenza infection. 
                    
 
Figure 10: Influenza infections are often characterized by weight loss. This model shows the differences in the 
amount of weight lost between ferrets who were treated with M2e-Lipo-DT+PHAD vaccine and ferrets who 
received only blank liposome.  
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Figure 11: TCID50 values, as determined via HA assays, show approximate viral titers across a 7-day infection 
period.  
 
 After the 10 minutes observations, ferrets were anesthetized using isoflurane and 
ketamine.  While under the effects of anesthesia, ferrets from both groups were weighed 
and their temperatures were measured daily.  Typically, when ferrets are challenged with 
an influenza infection, the ferret responds with signs, such as weight loss and a fever.  The 
relationship between the infection time period and morbidity signs are illustrated in Figure 
9 and Figure 10.  Initially, both ferret groups were running about the same temperature at 
approximately 39° C. After Ca09 challenge, both groups had temperatures between 38° C 
and 40°C.  On average ferrets have a body temperature of approximately 38.83° C. 
Following intranasal inoculation with Ca09, most of the ferrets, regardless of vaccination, 
exhibited a low-grade fever.  As shown in Figure 9, ferrets that received vaccination prior to 
challenge had lower temperatures, as a whole, in comparison to the blank liposome 
recipients.  After infection, ferrets from both groups showed signs of weight loss, especially 
by day 2 post infection.  Following day 2 post infection, the ferrets from the vaccinated 
group experienced a less drastic reduction in weight.  In the unvaccinated group, the weight 
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loss shown was more drastic, dropping to just under 95% of their original body weight as 
denoted by Figure 10.  By day 6 and 7 post challenge, the groups weighed about the same 
in terms of percent-initial body weight.  
 After taking the weight and temperatures of each ferret, both the vaccinated and 
unvaccinated groups were subjected to nasal washes using 1x PBS (pH =7.43).  The nasal 
washes collected were serially diluted and plated over a 48 well plate containing MDCK 
cells as previously described.  The plates were allowed incubate for 4 days at 37° C before 
measuring the viral content using the HA assay.  Results from the HA assay were 
determined on the basis of the formation of a pellet, signifying a negative result, or 
hemagglutination, proving a positive result.  Based on the data gathered, the vaccinated 
ferrets have reduced initial viral titers (approximately 106.5) compared to the unvaccinated 
group which exhibited viral titers as high as 108.  This trend continued throughout the 
course of infection as shown in Figure 11.  Day 3 showed that 2 out of the 3 ferrets in the 
unvaccinated group had a lower viral titer than the vaccine recipients, but by the next day 
the groups had similar titers again. This trend renewed again by day 5. Finally, vaccine and 
blank liposome recipients cleared the infection by 7.   
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Figure 12: M2e-based ELISA results depict how prior vaccination and subsequent antigen exposure, or the 
lack thereof, affects the generation of an anti-M2e IgA response. 
 
                  
Figure 13: M2e-based ELISA results demonstrate the efficacy of the M2e vaccine in ferrets in relation to anti-
M2e IgG generation during a 7-day post infection period versus the IgG humoral response of blank liposome 
recipients.   
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Figure 14: HAI assays demonstrate the ability of each ferret, vaccinated or not, to neutralize via sera antibody-
viral HA interactions. The unvaccinated group exhibited the same HAI titers as the vaccinated group. 
 
 Once anesthetized on days 1, 3, 5, and 7 following infection with the Ca09 virus, 
sera from the vaccinated and unvaccinated groups was collected and treated in a manner 
previously described.  The treated sera were used in a variety of assays, such as M2e-based 
ELISAs and HAI assays.  To assess the formation of anti-M2e IgG and IgA in response to 
Ca09 challenge, M2e-based ELISAs were employed in a manner previously described.  
Analysis of the absorbances produced via Bio Tek EL808 revealed that anti-M2e IgA titers 
in the vaccinated group, immediately after infection, were exponentially higher than the 
ferrets who were inoculated with blank liposomes (Figure 12).  Furthermore, one of the 
ferrets in the vaccinated group exhibits a reduction in the anti-M2e IgA titers on day 7, 
correlating with the clearance of the pathogen.  
 M2e-based ELISAs that were utilized to determine the amount of anti-M2e IgG in 
sera revealed that the ferrets who were vaccinated had a multiple fold increase in anti-InA 
IgG in response to Ca09 challenge compared to their unvaccinated counterparts.  
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Vaccinated ferrets maintain higher titers of anti-M2e IgG throughout the course of 
infection ranging from 76 to 412.  In comparison, the blank liposome group did not mount 
a great IgG mediated humoral response against the M2e protein following the induction of 
morbidity displaying a constant anti-M2e IgG titer of approximately 10.  Even as the Ca09 
infection persisted, M2e-based ELISAs did not detect the significant production of anti-
M2e IgG antibodies in ferrets who were inoculated previously with blank liposomes.  
Figure 13 shows the relationship between anti-M2e IgG titers in the vaccinated and 
unvaccinated ferrets over the 7-day infection period. 
 Ferret sera collected on days 1, 3, 5, and 7 post-infection with the Ca09 influenza A 
virus was also used in HAI assays to assess the ability of antibodies present in the sera to 
interact with the HA surface protein of the virus.  Initially, neither the vaccine or blank 
liposome recipients produced anti-HA antibodies against the Ca09 influenza virus.  As the 
infection proceeded, the concentration of anti-HA antibodies present in the sera of both 
groups increased exponentially to 640 with one ferret in the vaccinated group reaching 
titers of 1280.  The most notable increases in the ability of antibodies present in the ferret 
sera to interact with Ca09 HA was on days 5 and 7 as shown by Figure 14.  Thus, the 
vaccinated group produced higher levels of antibodies against M2e, indicating that the 
vaccine induced immunity against this protein.  However, both vaccinated and 
unvaccinated animals produced the same level of anti-HA against the Ca09 pathogen, and 
responded similarly to challenge.  The impact of these findings on the use of M2e as a 
universal vaccine are discussed below.  
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CHAPTER FOUR 
 
Discussion: 
 
Why Ferrets? 
 The ferret is a reputable model organism when it comes to researching influenza 
viruses.  Unlike murine-based models, ferrets are a particularly useful model when it comes 
to studying the pathogenicity and transmissibility of influenza, because this mammalian 
species can be infected, without viral adaptation, by both human and avian variants of the 
influenza virus (Matsuoka, Lamirande, and Subbarao 2009).  This is further 
complemented by the ferret’s analogous respiratory structure to humans. As such, the viral 
interactions between host and pathogen are very similar (Belser, Katz, and Tumpey 2011).  
The ferret demonstrates usefulness when it comes to modeling viral transmission due to 
the induction of sneezing following infection (Matsuoka, Lamirande, and Subbarao 2009).  
Sneezing results in the expelling of virus in the form of respiratory droplets, a sign 
commonly seen in human patients with influenza.  Another sign exhibited by ferrets that is 
common in humans diseased with influenza is the induction of a fever (Belser, Katz, and 
Tumpey 2011).  In tandem with demonstrating signs similar to those found in humans, is 
the ability to vaccinate ferrets and reduce viral spread. 
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Why the M2e-Lipo-DT+PHAD Vaccine? 
 The M2e-Lipo-DT-PHAD vaccine was selected for this study for many reasons.  
The first motive for using this vaccine was due to the vaccine’s ability to display multiple 
antigenic molecules, such as the exhibition of antigenic peptides attached to a lipid tail that 
is embedded into the liposome itself (Zaman, et al. 2016).  Conjunction of lipid tails to 
protein spacers and antigen proteins leads to better recognition by B cell epitopes 
generating a more immunogenic response (Ingale, et al. 2007).  This lipid-protein-M2e 
antigen conjugation is a favorable design, because antigen peptides by themselves are 
poorly immunogenic. However, through the covalent attachment of a peptide, such as M2e 
antigen, to a carrier protein, a stronger cell-mediated response is induced (Yussef, 
Pierobon, Reverstat, and Lennon-Duménil 2013). In addition, the liposome and associated 
peptides are potent activators of toll-like receptors (TLR), such as TLR-2, and other 
aspects of innate immunity (Zaman and Toth 2013).  Complementary to TLR-2 responses, 
is the affinity that antigen presenting cells (APCs) have for liposomes (Watson, Endsley, 
and Huang 2012).  This allows for a more “natural” immune response in which the APC 
phagocytizes antigen and delivers it to peripheral immune sites.  Next, is the ability of the 
M2e-Lipo-DT-PHAD vaccine to generate an IgA mucosal immune response (Lee and 
Nguyen 2015).  This begins with the intranasal delivery of the vaccine.  The nasal route 
mimics the natural way that influenza is transmitted from one host to another.  Intranasally 
delivery of the M2e-Lipo-DT-PHAD vaccine allows for the potential to generate defensive 
immunity against pathogens, such as influenza, that spread through mucous portals.  
Furthermore, the liposome and encapsulated DT has been shown to generate a strong IgA 
response through the formation of modulating epitopic constructs that stimulate IgA 
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secreting B cells.  The M2e-Lipo-DT-PHAD vaccine platform demonstrates the capability 
to stimulate a cell-mediated response, such as the activation of CD4+ cells, which aid in the 
process of the humoral response (Mozdzanowska, et al. 2005).  In previous human 
vaccinations, it has been determined that liposome-based vaccines are safe for human use 
(Watson, Endsley, and Huang 2012).  
 
Post-M2eA-Lipo-DT+PHAD Vaccination 
 Current vaccines are designed with the sole intent of targeting the subunits of the 
HA and NA surface proteins of the influenza virus, thus neutralizing the pathogen through 
the production of anti-HA or anti-NA antibodies (Kendal, Maassab, Alexandrova, and 
Ghendon 1987).  This directive is problematic due to the high mutation rate of HA and 
NA in conjunction with the concurrent circulation of additional viral strains (Hannoun 
2013).  As a result of influenza’s tendency to antigenically shift and drift, the production of 
vaccines is dampened (Schotsaert, Filette, Fiers, and Saelens 2009).  However, this 
hindrance could be averted through the addition of a more conserved peptide, such as the 
ectodomain of the M2 protein.  9 out of the 24 amino acids that compose M2e are highly 
conserved across all influenza strains (Wu, et al. 2007). It is due to the conserved peptide 
sequence that makes M2e a promising vaccine candidate.  This is further supported by 
previous studies that suggest that M2e-based vaccines convey cross-protection against 
multiple influenza strains in mice, rhesus monkeys, and ferrets (Fan, et al. 2004).  
 In line with the hypothesis, the results gathered from the post vaccination of ferrets 
suggest that a liposome-based vaccine incorporating multiple peptide antigens, such as M2e 
peptides and DT, and a self-adjuvanting glycolipid (PHAD) in ferrets has been identified.  
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It has been demonstrated that not only is this vaccine capable of eliciting a significant IgG 
humoral response to the M2e antigen, M2e, but due to the intranasal delivery, in tandem 
with the vaccine design, was able to generate an IgA response as well.  The unvaccinated 
group did not develop a humoral response against Ca09 M2e. However, despite the 
exceptionally high anti-M2e humoral response in vaccinated ferrets, the antibodies 
produced during the vaccination period were shown to be non-neutralizing in function and, 
as was expected, did not have an affinity for Ca09 HA.  This was illustrated through the 
microneutralization assay and HAI assay, respectively. These assays introduced the sera of 
ferrets that had been vaccinated, and thus contained anti-M2e antibodies, to the Ca09 
influenza A virus.   
 There are multiple explanations concerning why the anti-M2e humoral response 
does not neutralize the infectious agent.  The first is that the expression of M2e on a virion 
is low in comparison to HA and NA whereas an infected cell abundantly expresses M2e 
proteins on the surface of the cell (Bakkouri, et al. 2011).  Due to the low concentration of 
M2e present on a virion, antibodies are less likely to target the protein.  Furthermore, if 
antibodies bind to the ectodomain of M2e, it doesn’t necessarily block the M2 channel, so 
a pH change can still be induced allowing for viral replication to continue. However, it is 
worth using M2e complemented vaccines to employ other antibody-mediated effector 
functions, such as ADCC, to destroy infected cells (Fiers, et al. 2009). In short, when anti-
M2e antibodies bind to the M2e that is expressed by infected cells, the Fc portion of the 
antibody is exposed to other effector cells, such as natural killer cells and macrophages.  
The effector cells will bind to Fc portion of the anti-M2e antibody via the FcgrIII and 
trigger the effector function of the bound cell (Bakkouri, et al. 2011).     
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Post-A/California/04/2009 Challenge/Relevancy to Superinfections 
 After the 34-day post vaccination period, both vaccinated and unvaccinated ferrets 
were challenged with Ca09 influenza A virus.  The ferrets who were vaccinated against M2e 
displayed an immediate IgA and IgG response compared to the ferret group that received 
blank liposomes suggesting immunological memory was generated against M2e.  Despite 
the vaccinated group having higher antibody titers, they displayed viral titers equivalent to 
the unvaccinated group as shown by Figure11.  This shows that the M2e vaccine was not 
strong enough to protect the ferrets against Ca09 infection, which suggests that the vaccine 
would need to be complemented with an HA or NA component. The unvaccinated ferrets 
did not elicit a natural, humoral response against M2e, which suggests that M2e does not 
natural elicit an immune response.   
 However, previous microneutralization data suggests that the antibodies were non-
neutralizing in function.  Extrapolation of microneutralization results coupled with the 
presence of reduced viral titers and an elevated anti-M2e humoral response suggests that 
these antibodies operating in an alternative manner.  The data produced from M2e-based 
ELISAs showed that following the challenge with Ca09 that vaccinated ferrets produced a 
substantial amount of anti-M2e IgA antibodies.  IgA is composed of two monomers linked 
by a J chain and a secretory unit (Abbas 2019).  Due to the secretory unit, IgA is able to be 
taken up by the basolateral side of mucosal cells without being degraded inside the cell and 
is transferred to the apical side where the infection is taken place (Renegar, Small, Boykins, 
and Wright 2004).  Given that IgA is the antibody primarily associated with mucosal 
immunity, it is partially responsible for reducing the viral load present in the respiratory 
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system vaccinated ferrets as seen by days 1-3 post infection.  Again, the unvaccinated ferrets 
did not elicit an anti-M2e IgA response showing M2e is not innately immunogenic.  
 The results derived from post vaccination and post infection show that the anti-M2e 
IgG being produced is not performing a direct neutralization function, but it is binding to 
M2e that is expressed on the surface of influenza-riddled cells. The mechanism triggered 
through the binding of anti-M2e IgG to M2e on the surface of infected cells has yet to be 
defined, but it has been shown in previous research that major contrivances of immunity 
are marking for opsonophagocytosis, the activation of the complement cascade, resulting in 
the formation of the membrane attack complex, and functional FcgRIII interactions that 
yield ADCC (Jegerlehner, Schmitz, Storni, and Bachmann 2004).  Bakkouri et. al, 
produced results that demonstrated the necessity of FcgRIII interactions of effector cells 
with anti-M2e antibodies bound to influenza-diseased cells in clearing the influenza related 
morbidity (Bakkouria, et al. 2011).  As a result, it is thought that effector cells in 
conjunction with anti-M2e antibodies, are reducing the spread of the disease through 
ADCC.  Again, these antibodies have been shown to be non-neutralizing in nature and lack 
specificity for HA, as determined by HAI assays, suggesting an alternative mode of 
operation which requires further exploration.  
  The M2e-Lipo-DT-PHAD vaccine induced antibodies against M2e, but the 
antibodies were not neutralizing and did not initially reduce viral load, in comparison to the 
ferrets who received blank liposomes during the first three days following Ca09 challenge.  
This illustrates that while M2e is a potential vaccine candidate due to its conserved nature 
between influenza A strains, it is an infection permissive vaccine that may not be protective 
if delivered alone.  It was not until days 5-7 that a significant decrease, and eventual 
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clearance of the Ca09 pathogen was shown.  This correlates with an elevation in the 
production of anti-HA antibodies as shown by the day 5-7 of Figure 14.  Given that none of 
the ferrets produced anti-HA antibodies following vaccination and in turn did not have 
immunological memory against Ca09 HA, the reduction of virus in response to an anti-HA 
humoral response illustrates the importance of an immune response against HA is when it 
comes to reducing the pathogenicity of influenza.  The lack of production of anti-M2e 
antibodies versus the generation of an anti-HA humoral response in unvaccinated ferrets 
demonstrates that naturally the host generates an immune response based on antigen 
availability. Since the HA concentration on IAV is exponentially higher than the M2e 
content present, the natural immune response will be towards HA.  Future vaccines that 
evaluate M2e should consider including HA and NA components in the vaccine design.  
This vaccine could be tested against influenza viruses that have undergone antigenic drift 
where the anti-HA or anti-NA response may not be 100% protective.  However, in these 
situations the immunity induced against the HA, NA, and M2e may complement each 
other and provide complete protection against this drift variant.  
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CHAPTER FIVE 
 
Conclusion: 
Contextualizing for the Future 
 What do these results suggest for continuing the development of M2e-based 
vaccines? It illustrates that individuals who have been vaccinated with an M2e-based 
vaccine will potentially contract influenza because the humoral response induced against 
M2e does not protect against immediate morbidity.  According to previous studies, the 
mortality rate associated with influenza infections are primarily due to complications 
inflicted by secondary bacterial infections, such as those caused by S. pneumoniae and S. 
pyogenes (Chaussee, et al. 2011).  The data of this study illuminates the fact that since anti-
M2e antibodies do not neutralize the influenza virus results illustrate that the M2e-Lipo-
DT-PHAD vaccine is an infection permissive vaccine.  While it is imperative to explore 
the utility of M2e peptides for universal vaccine candidacy, it is equally as important to 
realize the limitations of using M2e as the sole vaccine peptide despite its obvious 
advantages, such as its conserved nature and inexpensive production.  The permissibility to 
influenza morbidity, despite vaccination, leaves patients susceptible to subsequent infection, 
and potentially mortality (Peltola and McCullers 2004).  Instead, M2e should be included 
in conjunction with HA and NA content that is utilized in contemporary trivalent and 
quadrivalent vaccines.  This claim is supported by the data produced by this experiment, 
which recognizes the importance of humoral immunity against HA in clearing influenza 
infections.   
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 If M2e is to be incorporated in vaccines, it is essential to understand the immune 
response being induced.  It has been shown that a humoral response against M2e is not 
based on neutralization, but rather other mechanisms, such as opsonophagocytosis, 
complement activation, and ADCC (Fiers, et al. 2009). The future of this project aims to 
characterize these responses, specifically those related to ADCC.  In order to assess the 
contribution of anti-M2e antibodies to activation of the ADCC pathway, the Huber lab 
seeks to carry out similar studies as the ones conducted in this project.  However, in 
tandem with ELISAs, microneutralization assays, and HAI assays, an ADCC assay will be 
utilized to define the interactions anti-M2e IgG and IgA play in the activation of effector 
cells, such as natural killer cells and respiratory resident macrophages (Jegaskanda, et al. 
2013).  A similar research design can be utilized to assess the activation of the complement 
pathway via complement dependent cytotoxicity assays (Co, et al. 2014).  It is through 
characterizing these responses that a better understanding of the immunity induced by M2e 
based vaccines can be achieved.  This is crucial in generating the best immunonological 
memory possible to confront potential influenza infections that a patient may encounter.  If 
an immunization can be developed that inhibits primary infections, subsequent secondary 
infections can be prevented, drastically reducing the mortality rate associated with influenza 
infections.  
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